(reported by the Company)
No items found
ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect. The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):|
|Year of Commencement:||2019|
Lot 1, Level 2, HMRI Building, Kookaburra Cct, New Lambton Heights NSW 2305
|State:||New South Wales|